CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst

Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth of 39% and raised its full-year outlook. Regeneron Pharmaceuticals (NASDAQ: REGN) delivered 36% revenue growth as Dupixent’s global quarterly sales climbed to approximately $6.54 billion. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX), meanwhile, reached its enrollment target in a randomized study of EP-104GI for eosinophilic esophagitis, or EoE, with an important interim analysis expected in December 2026. The EoE connection makes the story particularly interesting. Dupixent is already approved for the disease, while Eupraxia is developing a locally delivered, extended-release treatment that could compete for appropriate patients if clinical development succeeds and regulatory approval follows. That possibility remains conditional, but it gives December’s data a commercial context beyond the usual clinical-trial calendar. The unifying theme is precision: identify disease risk more effectively, deliver treatment more intelligently and translate clinical value into durable demand. For many watching healthcare stocks, that is more compelling than another invitation to admire a molecule and return in a decade.

CareDx Earnings Bring Growth, Profitability and a Broader Platform

CareDx’s third-quarter 2026 results give its bullish case something pleasantly conventional: revenue growth accompanied by profitability. The company reported approximately $139 million in revenue, $19 million in GAAP net income and $30 million in adjusted EBITDA, a non-GAAP profitability measure. Operating cash flow was $13 million. Management increased its full-year revenue outlook to $520 million to $530 million and its adjusted EBITDA outlook to $90 million to $100 million. CareDx is also broadening its commercial reach. Its transplant-testing foundation now sits alongside specialty oncology testing, cell-therapy capabilities and patient-support services, creating additional ways to apply its diagnostic and clinical infrastructure. The company’s SEC-filed annual report provides the underlying business context, while its latest quarterly release illustrates the portfolio’s evolution. The July 1 acquisition of privately held Naveris brought NavDx into the business. CareDx reported $12 million in third-quarter specialty oncology testing revenue following the acquisition, which involved $160 million in cash consideration and up to $100 million in contingent consideration. The growth figures nevertheless require careful interpretation. Testing-services revenue increased 65% to approximately $119 million, but the quarter included acquired revenue and $15 million recognized for tests performed in earlier periods, compared with $6 million of prior-period revenue a year earlier. Excluding prior-period revenue recognition, testing-services revenue increased approximately 58%, a comparison that still includes the acquisition’s contribution. CareDx also divested its laboratory-products business on June 30, affecting the composition of its reported revenue. The underlying picture remains constructive, but not every dollar of growth arrived through the same door.

AlloSure Kidney Data Add Clinical Weight to CareDx’s Commercial Case

CareDx’s expanding clinical evidence offers another reason to watch the business. An analysis from the Kidney Allograft Outcomes AlloSure Registry, or KOAR, evaluated 131 kidney-transplant recipients with borderline biopsy changes or T-cell-mediated rejection. An AlloSure Kidney level of at least 1%, measured within 30 days before biopsy, was independently associated with nearly three times the risk of graft loss or a decline of at least 30% in kidney function. The distinction is important: the finding supports risk identification. It does not establish that using the test itself prevents those outcomes. A separate randomized study involving 332 kidney-transplant recipients across seven European centers found that donor-derived cell-free DNA monitoring was associated with 49% fewer biopsies between months three and 12 than surveillance-biopsy monitoring. CareDx reported similar observed clinical and safety outcomes between the groups over the study period..An additional validation analysis involving 4,976 recipients and 6,827 biopsies supported rejection prediction under updated pathology criteria. Together, these findings strengthen the argument that molecular monitoring can help clinicians make better-informed decisions in transplant care. For many assessing CDNA, the potential commercial connection is straightforward: stronger clinical utility may support broader adoption and recurring testing demand. That remains an execution thesis, not a guarantee that every clinical finding becomes a reimbursement decision. Still, CareDx increasingly has something useful on both sides of the conversation: clinical evidence and financial results.

Regeneron’s Third Quarter Shows the Power of Commercial Scale

Regeneron offers the established-company version of biotechnology’s opportunity. Third-quarter 2026 revenue reached $5.116 billion, up 36% from a year earlier. GAAP diluted earnings per share increased 35% to $18.45, while non-GAAP diluted earnings per share rose 70% to $20.07. Three major medicines contributed to the performance:

• Dupixent global net sales increased 35% to $6.5405 billion, compared with $4.857 billion a year earlier.
• EYLEA HD U.S. net sales increased 62% to approximately $699 million.
• Libtayo global net sales increased 51% to $550 million..

Dupixent’s sales were recorded by collaboration partner Sanofi (NASDAQ: SNY), not booked in full as Regeneron revenue. Regeneron participates through the collaboration’s profit-sharing and other contractual arrangements. That accounting distinction is essential. A blockbuster can make a substantial contribution to earnings without every dollar of its sales passing through the same income statement. Regeneron’s Sanofi collaboration revenue increased as its share of antibody-commercialization profits rose to $2.575 billion from $1.456 billion. Higher Dupixent sales helped drive the improvement. Another benefit came from the full repayment of the Sanofi development balance at the end of the second quarter, which meant that balance no longer reduced collaboration revenue beginning in the third quarter.The science supplied demand. The contract supplied an additional lift to the economics.

Dupixent’s $6.54 Billion Quarter Puts EoE in a Larger Commercial Context

Dupixent’s growth is especially relevant to the emerging EoE discussion. The medicine is approved in the United States for adults and children aged one year and older who weigh at least 15 kilograms and have eosinophilic esophagitis. It also carries approvals across several other inflammatory diseases. An important boundary belongs beside the sales figure: the $6.5405 billion represents worldwide Dupixent sales across indications, not EoE-specific sales. Regeneron’s quarterly product-sales presentation does not separately identify the amount attributable to EoE. It would therefore be inaccurate to present the entire figure as the market available to an EoE competitor. Even with that limitation, Dupixent provides a clear example of an approved systemic biologic competing in EoE. Its prescribing information calls for 300 mg every week in EoE patients weighing at least 40 kilograms, with weight-based every-two-week dosing for smaller eligible patients. Regeneron and Sanofi are also continuing to build the clinical case. In May 2026, they reported Phase 4 REMODEL results showing significant and clinically meaningful improvements in esophageal distensibility, a measure of esophageal function, and disease-related structural changes versus placebo at week 24 in adults with EoE. That gives prospective competitors a meaningful standard to address. An approved medicine with growing sales and continuing clinical development does not tend to surrender its position merely because a newcomer has designed an attractive presentation.

Eupraxia’s EP-104GI Could Offer a Different Competitive Approach in EoE

Eupraxia’s opportunity is not to reproduce Dupixent’s approach. It is to establish whether local, extended-release treatment can offer a compelling alternative for appropriate patients. EP-104GI uses Eupraxia’s Diffusphere technology to deliver treatment through injections into the esophageal wall. The platform is designed to provide controlled drug release at the target tissue over an extended period. Its safety, efficacy, tolerability and duration of effect remain investigational. The competitive hypothesis is attractive: if EP-104GI demonstrates sufficiently durable symptom relief and improvements in tissue inflammation, with acceptable safety and procedural tolerability, it could offer an alternative to ongoing systemic treatment for some patients after approval. That is a potential positioning advantage, not an established clinical advantage. Dupixent is administered by subcutaneous injection, while EP-104GI involves an esophageal injection procedure. Treatment preference would depend on the eventual evidence, approved labeling, duration of benefit, procedural burden, access and reimbursement. The comparison is also not a head-to-head contest. RESOLVE compares EP-104GI with vehicle control, not Dupixent. The credible bullish argument is that a differentiated, durable local therapy could expand treatment choice and compete for a portion of EoE care if approved. Eupraxia would not need to challenge Dupixent across all of its indications for an EoE product to become commercially meaningful.

December 2026 Is the Next Major EP-104GI Milestone

Eupraxia reached its target enrollment of 120 patients in the blinded, placebo-controlled Phase 2b portion of RESOLVE. The 120th patient was enrolled and treated on October 12, with the milestone announced October 15. The study evaluates two EP-104GI doses, 120 mg and 160 mg, against vehicle control, with patients randomized equally among the three groups. Management said periodic reviews had confirmed that the planned sample size did not need to increase to support the study’s statistical objectives. That conclusion does not itself establish a positive efficacy result. The December 2026 interim analysis is expected to include:

• Symptoms, histologic findings and safety in the first 60 Phase 2b patients reaching six months.
• Additional available observations at three, nine and 12 months.
• Evidence that could help clarify whether treatment activity persists over clinically useful periods.

Histologic findings refer to changes in tissue examined under a microscope. In EoE, the commercial and clinical question is not simply whether patients report feeling better, but whether symptom improvement is accompanied by evidence of disease control. The December update is an interim Phase 2b analysis, not a final pivotal readout or an approval decision. Its importance lies in the possibility of providing more rigorous support for the treatment concept and informing later development For many following EPRX, that makes December a defined evidence checkpoint rather than a vague promise somewhere beyond the next financing.

Early Eupraxia Findings Offer Encouragement, With Clear Limits

Earlier open-label findings provide a reason to watch the randomized data. In the highest-dose Phase 1b/2a cohort, two of three patients maintained symptom remission through week 36. The durability signal is encouraging, but a three-person cohort cannot establish how a treatment will perform in a broader population. The October enrollment announcement also reported that more than 3,000 injections of EP-104GI or vehicle had been administered across the Phase 1b/2a and Phase 2b portions, with no treatment-related serious adverse events reported to that point. Those are individual injection administrations, not 3,000 patients or 3,000 separate treatment procedures. That distinction matters because treatment can involve multiple injections into the esophageal wall, but the company and many others are hoping that this will be a once a year therapy. The next task is to move from encouraging observations to controlled evidence. Biotechnology has never suffered from a shortage of promising beginnings. The premium belongs to programs that can sustain the story as the study design becomes more demanding.

Eupraxia’s Funding Gives the Clinical Program Room to Advance

Eupraxia’s balance sheet adds practical support to its development plans. At June 30, the company reported $52.4 million in cash and cash equivalents and $81.2 million in short-term investments. Management estimated that existing resources would fund operations into the second half of 2028. The second-quarter net loss was $14.5 million. Its SEC-filed annual information form also details financing activity, including a February offering that generated approximately $63.2 million in gross proceeds before commissions and expenses. The capital supports execution, while the additional securities remain relevant to the per-share equation A stronger funding position does not improve a drug’s biology. It does, however, give a company more room to complete the work needed to determine whether the biology deserves commercial backing.

Regeneron Has More Growth Levers Beyond Dupixent

Regeneron’s opportunity extends beyond one medicine or one quarter. An expanded Sanofi agreement added next-generation, long-acting antibodies to the collaboration. Regeneron received a $1 billion upfront payment expected to be recognized as collaboration revenue in the fourth quarter, with eligibility for up to $7 billion in additional development, regulatory and sales-based milestones. Those future milestones are conditional, not revenue already earned. The company also reported approximately 50 clinical product candidates and continued development across oncology, anticoagulation, obesity and other therapeutic areas. Its October 30 SEC filing formally furnished the quarterly results. There is a counterweight to the enthusiasm. Although EYLEA HD grew strongly, combined U.S. sales of EYLEA HD and standard-dose EYLEA declined approximately 1% year over year. The company continues to navigate competitive pressure and the transition between products. The constructive case is therefore not that every franchise is accelerating. It is that immunology, oncology, collaboration economics and a broad pipeline provide several potential sources of growth.

The Bullish Connection: Commercial Proof Meets Emerging Competition

CareDx, Regeneron and Eupraxia occupy different positions on biotechnology’s development curve. CareDx combines growing diagnostic revenue with expanding clinical evidence. Regeneron supplies commercial scale, strong earnings and a blockbuster immunology franchise. Eupraxia offers a more concentrated clinical-stage opportunity, with December data that could help determine whether EP-104GI has the characteristics needed to become a differentiated EoE treatment. The Dupixent connection sharpens the significance of Eupraxia’s program without eliminating its uncertainty. An approved treatment already serves EoE, while a potential future entrant is testing whether local, extended-release delivery can offer another useful option. Successful development and approval could create competition, but neither commercial adoption nor clinical superiority can be assumed. For many looking beyond biotechnology’s slogans, the appeal is increasingly measurable: revenue, earnings, clinical utility, funding capacity and defined trial milestones. The most compelling growth stories are not merely promising better medicine. They are steadily assembling the evidence that better medicine can become a better business.

The Sources

1. CareDx, third-quarter 2026 financial results, SEC-filed earnings release, October 29, 2026.sec
2. CareDx, 2025 Form 10-K, filed February 25, 2026.sec
3. CareDx, AlloSure Kidney and KOAR clinical-data announcement, October 22, 2026.businesswire
4. Regeneron, third-quarter 2026 financial and operating results, October 30, 2026.investor.regeneron
5. Regeneron, third-quarter 2026 earnings release with detailed product-sales tables.investor.regeneron
6. Regeneron, Form 8-K furnishing third-quarter results, October 30, 2026.sec
7. Regeneron, 2025 Form 10-K, filed February 4, 2026.sec
8. Dupixent, full U.S. prescribing information, revised April 2026.regeneron
9. Regeneron and Sanofi, Dupixent Phase 4 REMODEL results in EoE, May 5, 2026.newsroom.regeneron
10. Eupraxia Pharmaceuticals, RESOLVE enrollment-target announcement and December interim-analysis plans, October 15, 2026.investors.eupraxiapharma
11. Eupraxia Pharmaceuticals, second-quarter 2026 financial results, SEC Exhibit 99.3.sec
12. Eupraxia Pharmaceuticals, Annual Information Form, March 11, 2026, SEC Exhibit 99.1.sec
13. Eupraxia Pharmaceuticals, nine-month RESOLVE tissue-health and symptom data, April 21, 2026.investors.eupraxiapharma